2017 Pediatric Rheumatology Symposium

May 17-20, 2017. Houston, Texas.

View by Date

Jump to: View All • a [b] c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 131

Balancing JAK/STAT-signaling with tofacitinib may foster anti-inflammatory functions of human monocytes
Abstract Number: 65

Barriers at School for Children with Juvenile Idiopathic Arthritis (JIA) –A Patient Reported Outcome
Abstract Number: 47

Baseline characteristics of the first 123 patients enrolled in the Childhood Arthritis and Rheumatology Research Alliance Start Time Optimization of Biologic Therapy in Polyarticular JIA comparative effectiveness study
Abstract Number: 74

Benefit of Anakinra in Treating Pediatric Secondary Hemophagocytic Lymphohistiocytosis
Abstract Number: 9

Biologically-Based Approach for Classifying Chronic Childhood Arthritis
Abstract Number: 97

Bortezomib is Efficacious in the Treatment of Refractory Neuropsychiatric SLE with Psychosis
Abstract Number: 18

Bridging the gap between GWAS and mechanism in juvenile idiopathic arthritis using a novel high-throughput experimental screen

Jump to: View All • a [b] c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

2017 Pediatric Rheumatology Symposium

Balancing JAK/STAT-signaling with tofacitinib may foster anti-inflammatory functions of human monocytes

Barriers at School for Children with Juvenile Idiopathic Arthritis (JIA) –A Patient Reported Outcome

Baseline characteristics of the first 123 patients enrolled in the Childhood Arthritis and Rheumatology Research Alliance Start Time Optimization of Biologic Therapy in Polyarticular JIA comparative effectiveness study

Benefit of Anakinra in Treating Pediatric Secondary Hemophagocytic Lymphohistiocytosis

Biologically-Based Approach for Classifying Chronic Childhood Arthritis

Bortezomib is Efficacious in the Treatment of Refractory Neuropsychiatric SLE with Psychosis

Bridging the gap between GWAS and mechanism in juvenile idiopathic arthritis using a novel high-throughput experimental screen